ClinicalTrials.gg
RecruitingNCT07339059Updated Jul 28, 2026

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

A Phase 2 interventional study of Sacituzumab govitecan and Atezolizumab in Small Cell Lung Cancer ( SCLC ) and Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Bindu R Potugari. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Bindu R Potugari · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing atezolizumab in Small Cell Lung Carcinoma — 6 open to participants now, 7 under way, none of them phase 3. atezolizumab · Small Cell Lung Carcinoma.

Planned enrollment
14th of 19
35 · median 54
Started
2026
the only one that year
Phase 2
14 of 19
5 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
Bindu R Potugari

Among the 19 studies testing atezolizumab in Small Cell Lung Carcinoma, this one is the 14th largest by planned enrollment, is the only one that started in 2026, is one of 14 in phase 2, and was the 19th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

6 of the 19 studies testing atezolizumab in Small Cell Lung Carcinoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing atezolizumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination.

The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors.

Participants in the trial will:

  • receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient.
  • CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks.
  • provide tissue (optional) and blood for additional testing (learn about the cancer).
Read the detailed description

Small Cell Lung Cancer (SCLC) is a high-grade neuroendocrine tumor, accounting for nearly 15% of all lung cancers. It is characterized by rapid doubling time, high vascularity, apoptotic imbalance, and early widespread hematogenous metastasis. More than two-thirds of the patients present with extensive stage and only one-third of them present with limited stage confined to the chest. Prognosis continues to be poor with a 3yr relative survival rate of 13%. Despite high response rate with platinum-based chemotherapy, the median survival is limited in patients with advanced SCLC due to early recurrence. The addition of atezolizumab to platinum doublet in the extensive stage has shown only marginal improvement in both progression free survival (PFS) (5.2 months vs 4.3 months) and median overall survival (OS) (12.3 months vs 10.3 months) Similar results were observed with the addition of Durvalumab (median OS- 12.9 months vs 10.5 months). Therefore, there is a significant need to develop strategies that can sustain the response of platinum-based chemotherapy and thus prolong PFS and OS in advanced SCLC patients.

Transmembrane glycoprotein Trophoblast cell surface antigen 2 (TROP-2) is expressed at membranous and/ or cytoplasmic levels in many epithelial solid tumors including SCLC and is associated with poor prognosis. It plays an important role in carcinogenesis and tumor progression. Sacituzimab govitecan (SG) is an anti-TROP-2 antibody-drug conjugate composed of a humanized monoclonal antibody coupled with a toxic payload, SN-38, an active metabolite of irinotecan with a hydrolyzable linker. The antitumor activity/ efficacy of SG in SCLC was first noticed in first in human studies with >30% reduction of target lesions even after progression on prior topoisomerase I inhibitor. SG was evaluated in a phase I/II dose expansion/ escalation cohort to assess safety and efficacy in relapsed and refractory SCLC following 2 median prior therapies with a primary endpoint of objective response, assessed by imaging. A dose of 10mg/kg was determined to be dose-maximized efficacy and safety. Key treatment-related adverse events reported were neutropenia (57.8%) and diarrhea (56.2%). Patients with homozygous UGT1A1 allele status had an increased risk of neutropenia. Other common side effects reported were nausea/ vomiting, abdominal pain, anorexia, constipation, fatigue, anemia, and alopecia. Overall response rates of 14% (7/50) based on ITT (intention to treat) and 17% (6/36) for patients in the 10 mg/kg dose group, with a median duration of response of 5.7 months. Stable disease is noted in 42% of patients (21/50). In an open-label, multicohort Phase 2 study (TROPiCS-03), SG was evaluated in a second-line setting in patients who progressed after chemotherapy/immunotherapy in SCLC. Among 43 patients enrolled, the overall response rate was 41.9%, with a median PFS of 4.4 months (95% CI 3.81-6.11) and a median OS of 13.6 months (95% CI 6.57-14.78). All patients had treatment-related adverse events, and no AE led to treatment discontinuation.

The rationale for combining SG with immunotherapy:

Antibody-drug conjugate promotes antigen uptake and migration of dendritic cells in the tumor to tumor-draining lymph nodes, promoting T cell priming, expansion, and increased infiltration in the tumor microenvironment (TME). The infiltrating cytotoxic CD8 T cells can be stimulated with an immune checkpoint inhibitor, which effectively enhances and sustains the T cell response in the TME promoting an anti-tumor effect. SG in combination with pembrolizumab was evaluated after platinum-based chemotherapy which showed higher response rates with manageable toxicity in metastatic urothelial cancer. SG combined with atezolizumab has been evaluated in other solid tumors- breast cancer.

Given the responses in relapse and refractory SCLC with single agent SG and the potential additive effect with the combination of ADC and immunotherapy, investigators hypothesize that the addition of SG to atezolizumab/durvalumab after completion of induction platinum-based chemo-immunotherapy will improve and sustain the response rates and prolong the survival. To test the hypothesis, investigators aim to assess the clinical efficacy of the combination of SG and atezolizumab/durvalumab in a phase 2 study.

This is a prospective single-arm phase 2 study aiming to evaluate the clinical efficacy of the combination of maintenance SG and atezolizumab/ durvalumab in patients with extensive stage SCLC after completion of at least 4-6 cycles of platinum-based chemotherapy and immunotherapy. Participants with either stable disease or partial response and no evidence of disease progression as per RECIST 1.1 on restaging CT chest, abdomen, pelvis, and MRI brain will be enrolled before initiation of maintenance immunotherapy. Response and disease status for study eligibility will be based on the investigator's determination per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), and for CNS disease by mRECIST.

Eligible participants will be consented within 4 weeks after day 1 of the last cycle of chemo-immunotherapy. Patients will receive study treatment of the combination of SG at a dose of 10mg/kg on day 1 and day 8 along with atezolizumab 1200mg on day 1 every 3 weeks or Durvalumab 1500mg on day 1 every 3 weeks for 2yr or until disease progression, unacceptable toxicity, withdrawal of consent, loss of follow-up, or death, whichever comes first. Study treatment should be initiated within 3-6 weeks of the last chemo-immunotherapy after enrollment. Treatment beyond the progression may be allowed after discussion with PI if the participant continues to derive clinical benefit in the opinion of the investigator.

Safety assessments will be conducted before day 1 of each cycle. Dose modifications will be made as necessary and can occur mid-cycle if indicated or needed. Safety follow-up should occur approximately 30 days after the end of the treatment visit or before initiation of a new antineoplastic therapy, whichever occurs first. If a participant is unable to return for safety follow-up, this will not be considered a protocol deviation. Long-term follow-up will begin after safety follow-up and will follow the radiographic imaging schedule. Radiographic imaging should continue during long-term follow-up for participants who discontinue study drug treatment for any reason other than disease progression per RECIST 1.1, withdrawal of consent for follow-up, or death. Survival will be followed until death. For those who come off treatment for disease progression (or who progress during long-term follow-up), survival status will be assessed every 12 weeks via clinic visits, by phone contact, chart review, or other acceptable methods until the participant dies, withdraws consent, or the study is terminated.

The Henry Ford Cancer Data Safety Monitoring Board (DSMB) will review periodic safety analyses.

03

Conditions studied

  • Small Cell Lung Cancer ( SCLC )
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Keywords

  • atezolizumab
  • durvalumab
  • sactizumab govetican
  • small cell lung cancer
  • sclc
  • es-sclc
  • lung cancer
  • extensive stage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the trial.
  • Male or Female aged 18 years or above.
  • Participants must have a or cytologically confirmed diagnosis of small cell lung cancer (SCLC) and extensive stage at diagnosis or locally advanced disease and unable to receive curative intent radiation.
  • Participants must have received at least four cycles of platinum plus etoposide and at least 2-3 cycles of atezolizumab/ Durvalumab.
  • No evidence of progression on restaging CT CAP following 4-6 cycles of Chemo/IO from the last dose of the chemotherapy cycle.
  • performance status of 0-2
  • Patients must not have active uncontrolled , , and infections. Well-controlled infections on treatment will be allowed to participate in the trial.
  • Patients with stable and asymptomatic .
  • Adequate organ function - bone marrow, kidney, and liver.

Exclusion criteria

Exclusion Criteria:

  • Significant renal impairment requiring dialysis or hepatic impairment with end-stage liver disease.
  • Participants with .
  • Participants with a recent diagnosis of heart failure and acute coronary disease within 3 months.
  • Participants who are unable to receive immunotherapy with chemotherapy for induction will be excluded, or those immunotherapy was discontinued to manage immune-related adverse events
  • Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrolment.
  • Patients with prior exposure to , anti-PD-L1, or anti-PD-L2 agents or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4) within 12 months of the study is not allowed.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    SG and atezolizumab/durvalumab

    Sacituzumab govitecan 10 mg/kg via IV infusion on Day 1 and Day 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) AND Atezolizumab 1200mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks) OR Sacituzumab govitecan 10 mg/kg via IV infusion on Day 1 and Day 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) AND Durvalumab 1500mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks)

    Drug: Sacituzumab govitecan · Drug: Atezolizumab · Drug: Durvalumab

Interventions

  • Sacituzumab govitecan 10 mg/kg via IV infusion on Day 1 and Day 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment)

    Also known as: Trodelvy

  • Atezolizumab 1200mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks)

    Also known as: Tecentriq

  • Durvalumab 1500mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks)

    Also known as: Imfinzi

06

What researchers measure

Primary outcomes

  1. Disease Control

    To evaluate the rate of disease control at 12 weeks for patients with extensive stage small cell lung cancer treated with Sacituzumab govitecan (SG) plus atezolizumab or durvalumab as maintenance therapy after induction treatment with chemotherapy and immunotherapy. Disease Control at 12 weeks is defined as a best response by RECIST 1.1 of CR, PR, non-CR, non-PR, or stable disease assessed by RECIST 1.1 and reported within 12 weeks (+/- 2 weeks) from the initiation of study therapy. Participants not known to have disease control at 12 weeks will be coded as lacking disease control.

    Time frame: 12 weeks from study enrollment

Secondary outcomes

  1. Overall Survival

    Overall Survival (OS): OS is defined as the duration from study registration to death due to any cause. Patients last known to be alive will be censored at the date of last contact.

    Time frame: Through study completion, an average of 1 year

  2. Progression Free Survival

    Progression-free survival (PFS): PFS is defined as the duration from study registration to progression, symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free will be censored at the date of \[last contact or disease assessment\].

    Time frame: Through study completion, an average of 1 year

  3. Combination therapy toxicity

    To measure the frequency and severity of toxicity by incidence of treatment-emergent adverse events (TEAEs) and clinical laboratory abnormalities.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2029, 32 months after the start.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 32 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Jan 14, 2026
StartActual
May 14, 2026
Primary completionEst.
Feb 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07339059
Lead sponsor
Bindu R Potugari
Collaborators
Gilead Sciences
Responsible party
Bindu R Potugari (Thoracic Oncologist, Henry Ford Health System) — Sponsor-investigator
First posted
Jan 14, 2026
Start date
May 14, 2026
Primary completion
Feb 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Bindu Potugari, MD
Contact
bpotuga1@hfhs.org
888-734-5322

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacituzumab govitecan · Atezolizumab · Durvalumab

Start the discussion